JNK inhibition significantly sensitized very resistant ALL cells to GC by 30‐fold and reduced the GI50 of these cells to clinically achievable dexamethasone levels and at concentrations that clearly inhibited JNK signalling. The gene discussed is MAPK8; the disease is acute lymphoblastic leukemia.